Daewon Pharmaceutical Co., Ltd. (KRX:003220)

Market Cap	261.27B
Revenue (ttm)	590.70B
Net Income (ttm)	-16.04B
Shares Out	21.43M
EPS (ttm)	-748.20
PE Ratio	n/a
Forward PE	74.56
Dividend	300.00 (2.46%)
Ex-Dividend Date	Dec 27, 2024

Volume	10,479
Average Volume	23,302
Open	12,140
Previous Close	12,170
Day's Range	12,140 - 12,250
52-Week Range	12,110 - 15,910
Beta	0.21
RSI	35.93
Earnings Date	Mar 17, 2026

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1958
• Employees: 1,283
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 003220

Financial Performance

In 2024, Daewon Pharmaceutical's revenue was 598.16 billion, an increase of 13.51% compared to the previous year's 526.95 billion. Earnings were 14.21 billion, a decrease of -40.59%.